Heroin Addiction Treatment in Tennessee

What Is Heroin?

Heroin is a semi-synthetic opioid derived from morphine. It has no accepted medical use in the United States, is Schedule I under the Controlled Substances Act, and has existed as a street drug in roughly the same chemical form since the late nineteenth century. It is typically sold as a white or brown powder, a black sticky substance (“black tar heroin,” more common west of the Mississippi), or a rock-like form, and is most often injected, smoked, or snorted. The subjective effects — a rapid euphoric rush followed by hours of sedation — are the result of a full opioid-receptor agonist acting on the same receptors that respond to prescribed opioids like hydrocodone, oxycodone, and fentanyl. Physical dependence develops fast. Regular daily use over even a few weeks can produce withdrawal symptoms that drive continued use.

The practical reality is that, for the last several years, “heroin” and “fentanyl” have become the same product in most U.S. markets. The heroin sold on the street east of the Mississippi in 2024 and 2025 is, in the majority of samples, adulterated with illicit fentanyl, mostly fentanyl, or entirely fentanyl. DEA NFLIS drug-chemistry data show the fentanyl co-occurrence rate in heroin samples went from near zero in 2013 to roughly half of heroin samples nationally by 2022–2023, with state-level rates as high as 95% in parts of the Northeast. West-coast markets dominated by black tar heroin have lagged this transition, but the direction of travel is clear. For treatment purposes, we assume any patient presenting with heroin use disorder has significant fentanyl exposure, because the alternative assumption is unsafe.

That shift matters for everything that comes next on this page. It changes what the overdose risk looks like, it changes the window before buprenorphine can safely start, and it changes the kind of medical workup a patient who has been injecting for months or years needs. What hasn't changed is the treatment itself: buprenorphine-based MAT is still the most effective intervention we have, and it still works.

Signs of Heroin Use Disorder

Heroin use disorder is a medical condition, not a moral failing. For patients who inject, the signs are often more visible than for pill-first or snorting-only patients, but that doesn't make them more shameful — it makes them more medically urgent. Common signs include both universal opioid-use-disorder criteria and a specific cluster tied to intravenous use.

Universal opioid use disorder signs

• Physical tolerance. Needing more of the drug to achieve the same effect, or finding that a dose that used to hold you through the night no longer prevents early morning withdrawal.
• Withdrawal symptoms within hours of the last use. Muscle aches, sweating, nausea, diarrhea, restlessness, insomnia, anxiety, runny nose, watery eyes.
• Preoccupation. A large share of the day spent thinking about, obtaining, using, or recovering from use.
• Loss of control. Using more than intended, or being unable to stop despite repeated attempts.
• Continued use despite consequences. Maintaining use in the face of clear damage to health, relationships, work, housing, or legal standing.
• Isolation. Withdrawing from family, friends, or activities that used to matter — often because use has become a secret to protect.

IV-use-specific signs

• Track marks and chronic injection sites. Visible puncture scars, hyperpigmented linear marks over superficial veins, especially on forearms, hands, feet, and — when peripheral veins are exhausted — neck or groin.
• Collapsed or sclerosed veins. Veins that no longer flow, feel hard or rope-like, or disappear entirely. Patients often report progressively longer “hit attempts” and switching to harder-to-access sites.
• Skin abscesses and cellulitis. Recurrent red, warm, painful swellings at injection sites. These are bacterial infections, often Staphylococcus, and they don't self-resolve.
• Febrile episodes or new heart murmur. Fevers without an obvious source, night sweats, unexplained weight loss, or a new cardiac murmur can all indicate infective endocarditis. This is a medical emergency, not an outpatient problem — go to an ER.
• Unexplained back or spine pain. In an IV user, new severe back pain can be spinal osteomyelitis or an epidural abscess. Get it worked up.
• Hepatitis C exposure. Previous positive HCV test, a liver enzyme abnormality on an old lab, or any history of jaundice. CDC estimates the HCV prevalence among people who inject drugs exceeds 40%. Many are undiagnosed.
• HIV risk behavior. Shared needles, shared cookers, shared water, shared cotton — any of these carries HIV transmission risk. Testing is part of standard intake.
• Withdrawal fear shaping daily decisions. Life scheduled around dose timing. The morning hit before work. The extra injection before a family event because you know what 8 hours without one looks like.

You do not have to meet every item on this list. The formal DSM-5 threshold for opioid use disorder is 2 of 11 criteria in a 12-month period. Mild, moderate, and severe are all treatable — and treatment earlier is almost always easier than treatment later.

Heroin Withdrawal: Timeline and Symptoms

Heroin withdrawal is medically uncomfortable but not typically life-threatening in otherwise healthy adults. It is, however, severe enough that many people relapse simply to stop the symptoms, and that's not weakness — it's physiology. Medication-assisted treatment is designed specifically to prevent withdrawal rather than force you to endure it.

Heroin is a relatively short-acting opioid. Pure heroin withdrawal onset is typically 6 to 12 hours after last use, peaks on day 1 to 3, and the acute phase resolves over 5 to 7 days, with post-acute symptoms lingering longer. A general timeline looks like this:

• First 6 to 12 hours after last dose. Onset of early symptoms: anxiety, restlessness, irritability, yawning, watery eyes, runny nose, muscle aches, sweating, craving. Sleep becomes difficult.
• Day 1 to day 3 (peak). Full clinical picture: nausea, vomiting, diarrhea, abdominal cramping, chills alternating with sweating, dilated pupils, goosebumps (“kicking”), muscle and bone pain, profound fatigue, insomnia, intense cravings. Blood pressure and heart rate rise. This is when most unmedicated attempts to stop fail.
• Day 3 to day 7. Acute GI symptoms subside. Appetite begins to return. Sleep remains fragmented. Cravings stay strong. Low mood and anxiety may peak here as the body re-regulates.
• Week 2 and beyond (post-acute withdrawal). Low energy, difficulty concentrating, mood changes, anhedonia, intermittent cravings. Can persist weeks to several months if unmanaged. MAT dramatically shortens and softens this phase.

Fentanyl-contaminated supply changes this picture. Because most U.S. illicit “heroin” now contains fentanyl, real-world withdrawal often doesn't follow the clean textbook heroin timeline. Fentanyl stores in body fat and clears more slowly, so onset can be delayed (8–24+ hours instead of 6–12), the peak can be longer, and the window before buprenorphine can be safely started is often extended — commonly 24 to 72 hours after last use instead of 12 to 24. On top of that, because batch potency is inconsistent, two patients at the same stated dose can present with wildly different withdrawal severity. Starting buprenorphine too early after fentanyl exposure triggers precipitated withdrawal — a sudden, severe worsening of symptoms. Your provider will use a COWS (Clinical Opiate Withdrawal Scale) score at intake to time induction correctly and avoid that.

How We Treat Heroin Addiction

At Restoration Recovery, heroin use disorder is treated with a combination of medication and psychosocial support, and — where clinically relevant — integrated care for the medical conditions that often come with years of IV use. Every opioid patient is evaluated for medication-assisted treatment because the evidence supporting MAT is overwhelming: more than a 50% reduction in fatal overdose risk, significantly longer retention in treatment, and sharply lower rates of illicit opioid use. The medication options available are:

• Suboxone (daily film or tablet). A combination of buprenorphine and naloxone taken sublingually — available as a dissolving film or tablet placed under the tongue. Buprenorphine is a partial opioid agonist: it stabilizes cravings and prevents withdrawal at the same opioid receptors heroin and fentanyl are acting on, but with a ceiling effect on euphoria and respiratory depression. For heroin patients, same-day Suboxone induction is often clinically appropriate when COWS score is in the right range; for patients with heavy fentanyl exposure, induction may be delayed by 24–72 hours. The naloxone component is inactive when the medication is taken correctly; it's included to discourage misuse via injection.
• Sublocade (monthly injection). A long-acting extended-release form of buprenorphine administered once per month at our clinics. For patients whose dependence has been tied to the daily injection ritual itself, Sublocade can be particularly useful — it removes the dosing decision from the daily routine and holds steady blood levels for the full month. Per FDA labeling, Sublocade requires at least 7 days of transmucosal buprenorphine (Suboxone) before the first injection.
• Brixadi (weekly, bi-weekly, or monthly injection). Another extended-release buprenorphine injection, with flexible dosing intervals. Brixadi's weekly and bi-weekly options can be helpful for patients who are still finding the right maintenance dose, who want a shorter interval than Sublocade's monthly cadence, or whose insurance coverage differs between the two products. Like Sublocade, Brixadi is ordered per-patient and administered at a follow-up visit once the medication arrives.

Medication alone is effective. Medication paired with behavioral support and medical follow-through is more effective. We pair MAT with:

• Individual counseling with licensed therapists experienced in substance use disorder — including the specific trauma history common in long-term IV use, the grief around lost relationships, and the hard work of rebuilding a life that no longer revolves around drug-seeking.
• Certified peer support from specialists who have lived experience with recovery themselves. Many of our peers have walked the heroin-to-recovery path; that conversation often lands when a clinical one doesn't.
• Intensive outpatient programming (IOP) for patients who benefit from a more structured treatment schedule — delivered in a group format by design. IOP is the only group-setting service we offer, and it's a separate, structured program rather than an informal group activity.
• Integrated behavioral health for co-occurring conditions — anxiety, depression, trauma/PTSD, and bipolar or psychotic spectrum disorders are common in long-term heroin patients and directly affect retention in treatment. We address them rather than hand them off.

Integrated Hepatitis C Care

Because injection drug use is the dominant driver of hepatitis C transmission in the United States and prevalence among people who inject drugs exceeds 40%, we integrate HCV testing and treatment into our MAT program rather than running them as parallel referral tracks. Universal HCV screening is offered at intake for any patient with injection history, and for patients who test positive, we treat hepatitis C in-house. Modern treatment is an 8-to-12-week course of oral direct-acting antivirals with a cure rate above 95%, and there is no requirement to stop using before starting HCV therapy — starting HCV treatment while stabilizing on MAT is standard. Our hepatitis C care page covers the program in detail.

Restoration Recovery is an outpatient clinic. We do not provide medical detox or residential care. For most patients with heroin use disorder, a formal inpatient detox is not required — MAT can begin at the appropriate COWS-score window after last use, under clinical supervision. For patients who need a higher level of care first — active endocarditis, osteomyelitis, severe untreated co-occurring psychiatric illness — we coordinate with regional referral partners and stabilize you on MAT as soon as you're medically cleared to start outpatient treatment.

What to Expect at Your First Appointment

Your first visit typically lasts 60 to 120 minutes and follows a four-step clinical flow:

1. Intake. You'll complete paperwork and a clinical intake. For opioid use disorder, this includes a DSM-5 assessment to confirm the diagnosis and its severity (mild, moderate, or severe based on the 11 criteria met in a 12-month period), and a COWS (Clinical Opiate Withdrawal Scale) score to measure your current withdrawal state. The COWS score is especially important for heroin patients in the fentanyl era — it guides whether you're clinically ready to start buprenorphine the same day, or whether we need a longer interval to avoid precipitated withdrawal.
2. Counseling. You'll meet with a counselor to discuss your substance use history, any previous treatment, any co-occurring mental health conditions, your injection history (if any), and your personal recovery goals. For patients with IV use, this is also where we document risk factors for HCV, HIV, and skin-and-soft-tissue infections so the medical evaluation can focus on what matters.
3. Doctor evaluation. A medical provider reviews your intake, COWS score, and counselor notes. They walk you through medication options (Suboxone, Sublocade, Brixadi), explain onset, side effects, and induction timing, and answer your questions. For IV patients this is also where we discuss HCV screening, HIV testing, liver function, and any current or recent infectious concerns (abscess, cellulitis, fevers, murmur).
4. Prescription (and injection ordering, if chosen). If clinically appropriate, you leave the same day with a Suboxone prescription. If you prefer the extended-release route, your provider will order Sublocade or Brixadi during this visit — we don't stock injections on-site — and you'll continue on Suboxone as a bridge. Your injection appointment is scheduled for a follow-up once the medication arrives, typically after a short stabilization period on Suboxone (Sublocade's FDA label requires at least 7 days of transmucosal buprenorphine before the first injection).

Bring a valid photo ID, your insurance card if applicable, and a list of any medications you currently take. If you've had prior HCV or HIV testing, bring what you have. If you've had a recent ER visit for endocarditis, cellulitis, or abscess, bring the discharge summary. If you'd like to see the full process walked through step by step before your visit, our guide on what to expect at your first Suboxone appointment covers it in more detail.

Why Medication-Assisted Treatment Works for Heroin

For many patients, the fear of withdrawal is what keeps them stuck. MAT removes that barrier — the medication prevents withdrawal rather than forcing patients to endure it — which is why it works when willpower alone doesn't. In the fentanyl-contaminated-supply era, that same mechanism is also the single most powerful overdose-risk reduction available: if you're not in withdrawal, you're not chasing your next dose from an unknown batch of an unknown potency.

Medication-assisted treatment is endorsed as the standard of care for opioid use disorder by the Substance Abuse and Mental Health Services Administration (SAMHSA), the National Institute on Drug Abuse (NIDA), the American Society of Addiction Medicine (ASAM), and the World Health Organization. For heroin and illicit-opioid dependence specifically, the original buprenorphine trials and subsequent large-scale cohort studies have been running for over twenty years, and the result has been consistent.

Large-scale evidence shows that patients with opioid use disorder who receive buprenorphine-based MAT:

• Experience more than a 50 percent reduction in the risk of fatal opioid overdose
• Stay in treatment significantly longer than those receiving counseling alone
• Report fewer cravings and lower rates of illicit opioid use
• Are more likely to maintain employment and stable housing during recovery
• Have lower rates of infectious disease transmission associated with injection use, including hepatitis C and HIV

There's a heroin-specific clinical reality worth naming. Because the illicit opioid supply has been functionally replaced by fentanyl, the overdose risk of a relapse is not the same risk it was ten years ago. The difference between a patient's tolerance and an unknown-potency batch of fentanyl is, in many cases, the difference between survivable and not. The evidence for MAT was strong before the fentanyl era; in the fentanyl era, the case for starting treatment today instead of next month is simply stronger. Patients on buprenorphine who do have occasional breakthrough use also have measurably lower overdose risk during those events than patients off medication.

MAT is not a replacement of one drug with another. Buprenorphine's partial-agonist pharmacology gives it a ceiling effect on euphoria and respiratory depression that full agonists like heroin, oxycodone, and fentanyl don't have. Blood levels stabilize, the daily cycle of peak and crash disappears, and the neurological drive toward continued use recedes. Patients can engage in counseling, address the medical problems they've been ignoring, rebuild relationships, and return to work.

Harm Reduction, Honestly

We aren't going to pretend every heroin patient walks in on day one ready to stop, and we aren't going to moralize about what a patient did between the decision to come in and the first appointment. The honest practical reality is that small choices make a measurable difference in survival: carry naloxone (Narcan is available over the counter at pharmacies nationwide), don't use alone (or use the Never Use Alone hotline at 1-800-484-3731), use fentanyl test strips when they're available, and avoid combining opioids with benzodiazepines or alcohol, which multiplies overdose risk. None of this replaces treatment. All of it reduces the chance that today's use becomes a fatal overdose before Monday's appointment. The most powerful harm-reduction intervention available is starting MAT — a more-than-50% reduction in fatal-overdose risk that no other intervention comes close to matching.

Why Restoration Recovery

Choosing where to start treatment matters. Restoration Recovery brings together the clinical depth, the practical access, and the kind of care that keeps patients in treatment long enough to get well.

• Chattanooga's longest-running outpatient addiction treatment clinic. Our providers have decades of clinical experience treating opioid and substance use disorders in Southeast Tennessee — through the prescription-opioid era, the heroin surge that followed, and now the fentanyl era. We've treated every version of this.
• Integrated hepatitis C care. HCV is the most common co-morbidity in long-term heroin patients. We test, treat, and cure in-house rather than handing you a referral and losing you between providers. Details on our hepatitis C page.
• CARF accredited. The Commission on Accreditation of Rehabilitation Facilities is the gold standard for outpatient addiction care — our accreditation is reviewed on an ongoing basis, not a one-time stamp.
• Four clinic locations across Southeast Tennessee and North Georgia, with telehealth follow-up available for established patients.
• Most major insurance accepted — TennCare, Georgia Medicaid, commercial plans, Medicare, and supplemental Medicare. Our patient services team verifies your benefits before your first visit so there are no surprises.
• Same-day Suboxone appointments in most cases. You don't have to wait weeks to start.
• One integrated team. Medical providers, counselors, certified peer support specialists, psychiatric care, and HCV treatment under one roof — not parallel referral tracks that leave you coordinating your own care.
• Licensed in both states. Licensed in Tennessee and Georgia, HIPAA compliant, 42 CFR Part 2 compliant — your treatment is confidential from the first phone call.

Insurance and Access

Restoration Recovery accepts most major insurance plans, including TennCare, Georgia Medicaid, a broad range of commercial plans, and Medicare (plus supplemental Medicare plans). Our patient services team can verify your benefits before your first appointment so you know exactly what to expect in terms of cost.

If you do not have insurance, contact us anyway. We can help you explore options and will walk you through self-pay pricing. For a full list of accepted carriers and details on the verification process, visit our insurance page.

Four Clinic Locations

We operate four outpatient clinics across Southeast Tennessee and North Georgia. All locations offer heroin addiction treatment with same-day appointments in most cases:

• Chattanooga, TN — 6141 Shallowford Rd, Suite 100, Chattanooga, TN 37421
• Cleveland, TN — Serving Bradley County and surrounding areas
• Soddy-Daisy, TN — Serving Hamilton County north and the Sequatchie Valley
• Ringgold, GA — Serving Catoosa County and Northwest Georgia

Telehealth follow-up visits are available for established patients who have completed their initial in-person evaluation. For directions, hours, and contact information, visit our locations page.

Frequently Asked Questions

Is it still heroin if it's really fentanyl?

Clinically, it doesn't matter. If you've been using what was sold to you as heroin over the last several years, your dependence is most likely driven by fentanyl, heroin, or a mixture of both. The treatment path is the same either way: buprenorphine-based MAT (Suboxone, Sublocade, or Brixadi), with induction timing guided by a COWS score. What does matter is that your provider knows to expect fentanyl exposure, because the pharmacology changes how long you need to wait before your first Suboxone dose. Tell us what you've been using, honestly — we've heard it.

How do I get tested for hepatitis C?

HCV testing is part of standard intake for any patient with injection drug use history. CDC now recommends universal HCV screening for all adults at least once, plus periodic re-screening for anyone actively injecting. If your test is positive, we treat hepatitis C in-house rather than handing you a referral — see our hepatitis C care page for details. Modern HCV treatment is 8 to 12 weeks of oral medication with a cure rate above 95%. You do not need to stop using to be treated; we start HCV treatment in patients stabilizing on MAT every week.

Can I start Suboxone if I'm still using?

You don't have to be in full withdrawal to call, and you shouldn't stop cold turkey on your own. What determines timing is a COWS (Clinical Opiate Withdrawal Scale) score at your first visit. For short-acting opioids like heroin, the typical induction window is 6 to 12 hours after last use. For fentanyl — which is what most illicit “heroin” in the U.S. now contains — the window is often 24 to 72 hours, because fentanyl stores in body fat and clears more slowly. Your provider measures COWS at intake and times the first dose so you don't risk precipitated withdrawal. “Still using” is not a disqualifier; it's the starting point for most of the patients we see.

Is naloxone (Narcan) really going to help if it's fentanyl?

Yes. Naloxone reverses fentanyl overdose, and it works. The caveats are practical, not pharmacological: because fentanyl is more potent, more than one dose of naloxone is sometimes needed, and because fentanyl is shorter-acting in the brain than some illicit drug users expect, a second overdose is possible after the naloxone wears off. That's why any reversal should be followed by calling 911 and observation. Carry naloxone, keep it where others can access it, don't use alone, and don't wait to see if someone “sleeps it off.” And understand that the single most powerful overdose-risk reduction available is being on buprenorphine-based MAT — it cuts fatal overdose risk by more than 50%.

What about endocarditis or other infections from IV use?

Injection drug use is a known cause of infective endocarditis (an infection of the heart valves), skin and soft-tissue abscesses, osteomyelitis, and blood-borne infections including hepatitis B, hepatitis C, and HIV. Hospitalizations for IDU-associated endocarditis rose roughly twelvefold in parts of the Southeast between 2010 and 2015, and about a third of these patients are also hepatitis C positive. If you have current or recent IV use and new fevers, night sweats, unexplained back pain, or a new heart murmur, get evaluated urgently — not at our outpatient clinic, but at an ER. Once you're stabilized, MAT is what prevents the next episode, and we coordinate the handoff.

Can I start treatment if I don't have veins left for labs?

Yes. Lab access is a real problem for long-term IV users, and it doesn't stop you from starting treatment. Most first-visit decisions — DSM-5 diagnosis, COWS score, Suboxone induction — don't require a blood draw that day. When labs are needed (liver function, HCV, HIV, pregnancy testing), our team works with phlebotomists experienced with difficult access, including hand, foot, and external jugular sites where appropriate. If that still doesn't work, oral-fluid and point-of-care testing fill in a lot of the gap. The goal is to get you on medication on day one and sort out the peripheral workup around that — not the other way around.

Take the Next Step

Heroin addiction is survivable, and treatment works — even in the fentanyl-contaminated era, even after years of daily use, and even when the last few attempts at quitting didn't hold. You don't have to figure this out alone, you don't need to have all the answers before you call, and you don't need to be clean before your first appointment. Our team will walk you through the process from your first phone call to your first visit and every follow-up after that.

Same-day appointments are available in most cases. Contact us today to schedule your evaluation, or call 423-498-2000 to speak with our team directly.